Selcaxen 40 MG (Selpercatinib)

Basic Product Information of Selcaxen (Selpercatinib) 40mg

How Selcaxen (Selpercatinib) Works

Selcaxen contains Selpercatinib, a small molecule designed to block the ATP-binding site of the RET receptor tyrosine kinase, with no evidence of covalent or irreversible binding. In certain cancers, chromosomal rearrangements create an abnormal RET fusion protein, or point mutations create an abnormally active mutant RET protein, both of which drive uncontrolled tumour cell growth.

In large-scale kinase screening, Selpercatinib was selective for 98% of the more than 300 non-RET kinases tested, meaning it has minimal activity against unrelated targets at clinically relevant concentrations. By inhibiting RET signalling with this high degree of selectivity, Selcaxen suppresses tumour growth in cancers driven by RET fusions or activating mutations, including RET-driven NSCLC, medullary thyroid cancer, and RET fusion-positive thyroid cancer.

Selcaxen is taken as a twice-daily oral capsule, and treatment is only appropriate for patients whose tumours have been confirmed to carry an eligible RET gene fusion or mutation, using an approved diagnostic test.

Indications for Selcaxen (Selpercatinib)

Selcaxen (Selpercatinib) is indicated for the following conditions:

Benefits of Selcaxen (Selpercatinib) 40mg

How to Take Selcaxen (Selpercatinib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Selcaxen treatment. Your oncologist will check liver function tests, blood pressure, and thyroid function before starting treatment and periodically thereafter, and will monitor for signs of bleeding and, where indicated, perform ECG monitoring for QT prolongation. Monitoring also includes assessment for hypersensitivity reactions, including fever combined with rash or organ dysfunction. Report any yellowing of the skin or eyes, severe headache, unusual bleeding or bruising, dizziness, palpitations, fever with rash, or signs of an underactive thyroid (fatigue, weight gain, feeling cold) to your doctor immediately.

Drug Interactions and Important Information

Avoid concomitant use of Selcaxen with strong CYP3A4 inducers, such as rifampicin, carbamazepine, and phenytoin, as these significantly reduce Selpercatinib exposure and may reduce effectiveness. If a strong CYP3A4 inhibitor must be used, a dose reduction is required, as detailed in the dosing section above. Avoid grapefruit and grapefruit juice during treatment.

Use with caution alongside other medicines that prolong the QTc interval. Women of childbearing potential should verify pregnancy status before starting treatment and use effective contraception during treatment and for a period after the final dose, as advised by their physician. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Selcaxen.

Side Effects and Precautions

Who Should Use Selcaxen (Selpercatinib)?

Selcaxen is suitable for adult patients with metastatic NSCLC carrying a RET gene fusion, and adult and paediatric patients aged 2 years and older with RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer requiring systemic therapy, confirmed by an approved RET testing method. It is prescribed by medical oncologists, thoracic oncology specialists, and endocrine oncology specialists experienced in biomarker-guided cancer therapy. A thorough medical assessment including RET testing, baseline liver function, blood pressure, and thyroid function is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Selcaxen under WHO-GMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Selcaxen is one of Everest’s specialty precision-oncology products, offering a bioequivalent alternative to Retevmo by Eli Lilly at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Selcaxen (Selpercatinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Selcaxen (Selpercatinib) from Mediaid Pharmacy?

Selcaxen represents one of the most precise treatment options available for RET-driven cancers, targeting the exact genetic alteration behind the disease. As the generic equivalent of Retevmo by Eli Lilly, it delivers the same active ingredient, Selpercatinib, with the same proven, highly selective RET-inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP-compliant standards and distributed globally by Mediaid Pharmacy, Selcaxen gives patients and families worldwide access to precision RET-targeted therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Selpercatinib option with worldwide delivery, Selcaxen from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Selcaxen (Selpercatinib)